Xeno Biosciences Overview
- Founded
- 2015
- Status
- Private
- Employees
- 4
- Latest Deal Type
- Series A
- Latest Deal Amount
- $9.4M
- Investors
- 8
Xeno Biosciences General Information
Description
Developer of a novel class of therapeutics designed to address the large unmet needs in obesity and related metabolic diseases. The company's therapeutics include a simple enteric-coated pill composed of components that deliver molecular oxygen to the lower gut, thereby enabling doctors to treat obesity with gastric bypass microbiome.
Contact Information
Website
www.xenobiosciences.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
- 411A Highland Avenue
- Suite 341
- Somerville, MA 02144
- United States
+1 (714) 000-0000
Xeno Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Later Stage VC (Series A) | 01-Oct-2021 | $9.4M | 00.00 | 0000 | Completed | Generating Revenue |
Xeno Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | 0,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Xeno Biosciences Patents
Xeno Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3045011-A1 | Pharmaceutical preparations and methods to manage weight and to modulate the gut microbiota | Pending | 30-Nov-2016 | 000000000 | |
| AU-2017368074-A1 | Pharmaceutical preparations and methods to manage weight and to modulate the gut microbiota | Pending | 30-Nov-2016 | 000000000 | |
| EP-3548008-A1 | Pharmaceutical preparations and methods to manage weight and to modulate the gut microbiota | Pending | 30-Nov-2016 | 000000000 | |
| EP-3548008-A4 | Pharmaceutical preparations and methods to manage weight and to modulate the gut microbiota | Pending | 30-Nov-2016 | 0000000000 | 0 |
| US-20200078397-A1 | Pharmaceutical preparations and methods to manage weight and to modulate the gut microbiota | Pending | 30-Nov-2016 | A61K33/40 |
Xeno Biosciences Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| David Beno Ph.D | Chief Executive Officer, Chief Scientific Officer & Board Member | ||
| Hasan Celiker Ph.D | Founder & Advisor |
Xeno Biosciences Board Members (3)
| Name | Representing | Role | Since |
|---|---|---|---|
| Jeff Arnold | Self | Board Member & Advisor | 000 0000 |
| Michael Koeris | Xeno Biosciences | Board Member | 000 0000 |
| Stan Rose | Xeno Biosciences | Board Member | 000 0000 |
Xeno Biosciences Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialXeno Biosciences Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Bantam Group | Angel Group | Minority | 000 0000 | 000000 0 | |
| Beacon Angels | Angel Group | 000 0000 | 000000 0 | ||
| Boston Harbor Angels | Angel Group | 000 0000 | 000000 0 | ||
| California Institute for Quantitative Biosciences | Accelerator/Incubator | Minority | 000 0000 | 000000 0 | |
| Founders Capital Partners | Venture Capital | Minority | 000 0000 | 000000 0 |
